HealthQuill Clinical trials
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
Vertex Pharmaceuticals Inc.’s Alyftrek drug got clearance from the Food and Drug Administration to expand its treatment for cystic fibrosis in people six years and older, according to a statement from the company.
Drugs Health Medical Research

Vertex gets US regulator’s nod for extended use of cystic fibrosis drug

Vertex Pharmaceuticals Inc.’s Alyftrek drug got clearance from the Food and Drug Administration to expand its treatment for cystic fibrosis in people six.

Read More
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a statement.
Uncategorized

Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults

Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.

Read More
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia syndrome (FCS), according to a statement.
Drugs Health Pharma

Ionis Pharma’s drug to treat rare genetic disease gets US regulator’s nod 

The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.

Read More
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Drugs Medical Pharma

AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients

The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.

Read More
Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US drug regulator.
Drugs Health Pharma

US drug regulator removes clinical hold on Novavax’s vaccines

Novovax Inc., will soon start enrollment for end-stage trials of its Covid-19-Influenza vaccine and stand-alone influenza jab following a nod from the US.

Read More
AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.
Drugs Health Pharma

AbbVie says schizophrenic drug fails in 2 mid-stage experimental trials

AbbVie Inc.’s two mid-stage trials of an investigational schizophrenia drug have failed to meet its primary goal, according to a company statement.

Read More
GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.
Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug 

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Drugs Health Pharma

Novartis to pay Monte Rosa $150m upfront for MGD drug candidates

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.

Read More